Focused On-demand Library for AFG3-like protein 2

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.

We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.

The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.

Our top-notch dedicated system is used to design specialised libraries for enzymes.

Fig. 1. The sreening workflow of Receptor.AI

It includes comprehensive molecular simulations of the catalytic and allosteric binding pockets and the ensemble virtual screening accounting for their conformational mobility. In the case of designing modulators, the structural changes induced by reaction intermediates are taken into account to leverage activity and selectivity.

Our library distinguishes itself through several key aspects:

The Receptor.AI platform integrates all available data about the target protein, including past experiments, literature data, known ligands, structural information and more. This consolidated approach maximises the probability of prioritising highly relevant compounds.
The platform uses sophisticated molecular simulations to identify possible binding sites so that the compounds in the focused library are suitable for discovering allosteric inhibitors and the binders for cryptic pockets.
The platform integrates over 50 highly customisable AI models, which are thoroughly tested and validated on a multitude of commercial drug discovery programs and research projects. It is designed to be efficient, reliable and accurate. All this power is utilised when producing the focused libraries.
In addition to producing the focused libraries, Receptor.AI provides services and end-to-end solutions at every stage of preclinical drug discovery. The pricing model is success-based, which reduces your risks and leverages the mutual benefits of the project's success.

partner

Reaxense

upacc

Q9Y4W6

UPID:

AFG32_HUMAN

Alternative names:

Paraplegin-like protein

Alternative UPACC:

Q9Y4W6; Q6P1L0

Background:

AFG3-like protein 2, also known as Paraplegin-like protein, plays a pivotal role in axonal and neuron development. It is an ATP-dependent protease essential for the degradation of specific mitochondrial proteins, facilitating neuron health and function. This protein is involved in the maturation of several key proteins within the mitochondria, including paraplegin and PINK1, and regulates mitochondrial dynamics through its interaction with OPA1 and GHITM.

Therapeutic significance:

AFG3-like protein 2 is linked to several neurodegenerative disorders, including Spinocerebellar ataxia 28, Spastic ataxia 5, and Optic atrophy 12. These associations underscore its potential as a target for therapeutic intervention in these diseases. Understanding the role of AFG3-like protein 2 could open doors to potential therapeutic strategies, offering hope for patients suffering from these debilitating conditions.